Clinical trial Recruiting at 1 site Interventional Ages 30 to 85

Probiotic Y7 cocktail to help with early Parkinson’s symptoms

Official title: Developing Precision Microbiota-Based Cocktail Modification Therapy to Delay the Progression of Parkinson's Disease - Use Preclinical Human Trials to Confirm the Impact of the Optimal "Probiotic Y7, Tryptophan and Branched-chain Amino Acid" Cocktail Formula on Early Stage Parkinson's Disease Patient

Run by Taipei Medical University · NCT07619560 · Data updated 2026-11-12

A 12-week randomized trial will test whether a probiotic Y7 cocktail helps people with early Parkinson’s disease by possibly improving motor, thinking, and everyday symptoms.

More Parkinson Disease (PD) trials

Quick facts

Study typeInterventional
Ages30 Years to 85 Years
SexAll
Enrollment120 (estimated)
SponsorTaipei Medical University
Academic / other
Locations1 site (Taipei)
StatusRecruiting
StartedMay 20, 2025
Main results expectedAugust 31, 2027
Study endsAugust 31, 2027
Registry record updatedJune 2, 2026
Trial IDNCT07619560 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 30–85 with early-stage Parkinson’s (stage 1–3) who respond to PD medications and have MRI-confirmed striatal degeneration without major illnesses.

Probably not a fit

Patients who do not experience a response to the probiotic cocktail or have contraindications may not see benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial uses preclinical human work to guide a two-arm randomized design, comparing the Y7 probiotic cocktail to placebo in adults with early-stage Parkinson’s disease. It will recruit about 120 participants (Hoehn and Yahr stages 1–3) and measure motor function, cognition, and non-motor symptoms as outcomes. The study will collect clinical data, biomarkers, and questionnaires to build a personalized prognosis model while evaluating any potential delay in disease progression. If results are favorable, the program may advance toward commercial development. The sponsor is Taipei Medical University, with participating hospitals in Taipei.

Why it matters

Potential benefit: If successful, the probiotic cocktail could slow progression of motor and non-motor symptoms in early Parkinson’s disease.

How similar studies have gone: Prior similar probiotic approaches in neurological conditions have shown mixed results; this study builds on preclinical human data to test a targeted Y7 formulation in PD.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Subject Inclusion Criteria:

1. Age between 30-85 years old.
2. Diagnosed with early-stage Parkinson's disease (Hoehn and Yahr scale stage 1-3).
3. Brain MRI confirms striatal degeneration in the basal ganglia region, with no history of stroke.
4. Responds to Parkinson's disease-related medications (e.g., Levodopa).
5. Free of any major or acute illnesses.
6. Able to comply with the 12 weeks intervention and required assessments for the study.

Exclusion Criteria:

1. Unable to complete interviews or has mobility issues.
2. Presence of major or acute illness before or during the study.
3. Co-existing intestinal co-infections, such as CDI, E. coli, Salmonella, Shigella, Campylobacter, plague, or cytomegalovirus.
4. Allergic to the intervention product.
5. Pregnant or breastfeeding women.

Where it's running

  • Taipei Medical University Hospital
    Taipei, Taiwan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.